Bart Lee Scott, MD
Dr. Scott is a medical oncologist specializing in the treatment of patients with MDS, and leukemia.Patient Care Philosophy:
Patient education is key so that the patient can guide the physician to meet his or her needs.
Title
- Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Assistant Professor of Medicine, Division of Oncology, University of Washington
Clinical Expertise
Myelodysplasia Clinic, Leukemia
Education And Training
- University of South Alabama, Mobile, AL, School of Medicine, 1991-1996
- Residency: Johns Hopkins Hospital, Internal Medicine, 1996-1999
- Fellowship: University of Washington, Seattle, WA, Medical Oncology, 1999-2000
- Fred Hutchinson Cancer Research Center, Seattle, WA, 2001-2004
Clinical Trials
Dr. Scott is the SCCA lead investigator for the following clinical trials:
- Azacitidine +/- Gemtuzumab for Post-Transplant Relapse for MDS, CMML and AML (FHCRC-2240)
- Reduced Intensity Conditioning vs.Myeloablative Conditioning for AML or MDS (2497)
- Oral Azacitidine for MDS, CMML and AML (2474)
